WoundClear™ is a novel, marine-based enzymatic drug, intended to aid in debridement of severe wounds.
- Partial and full-thickness wounds with eschar development, in conjunction with or as stand-alone debridement therapy
- Trauma wounds (abrasions, lacerations, second-degree burns, skin tears)
- Pressure ulcers
- Chronic vascular ulcers
- Diabetic ulcers
WoundClear™ utilizes the LCE1 fusion protein from trout to facilitate debridement of eschar (necrotic tissue) in severe wounds. It is currently in the discovery stage.
WoundClear™ development is led by Regenics, and supported by researchers at RISE AB (Sweden).
WoundClear™ is intended to support treatment of: